Net Cash Provided by (Used in) Operating Activities in USD of CRISPR Therapeutics AG from 2016 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Summary
CRISPR Therapeutics AG quarterly/annual Net Cash Provided by (Used in) Operating Activities history and change rate from 2016 to Q1 2025.
  • CRISPR Therapeutics AG Net Cash Provided by (Used in) Operating Activities for the quarter ending March 31, 2025 was -$53.9M, a 149% decline year-over-year.
  • CRISPR Therapeutics AG annual Net Cash Provided by (Used in) Operating Activities for 2024 was -$143M, a 45.2% increase from 2023.
  • CRISPR Therapeutics AG annual Net Cash Provided by (Used in) Operating Activities for 2023 was -$260M, a 47.5% increase from 2022.
  • CRISPR Therapeutics AG annual Net Cash Provided by (Used in) Operating Activities for 2022 was -$496M, a 192% decline from 2021.
Net Cash Provided by (Used in) Operating Activities, Quarterly (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Operating Activities, Annual (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Annual Change (%)

CRISPR Therapeutics AG Quarterly Net Cash Provided by (Used in) Operating Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 -$53.9M -$164M -149% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-06
Q1 2024 $110M +$101M +1147% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-06
Q1 2023 $8.8M +$144M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q1 2022 -$135M -$34.6M -34.3% Jan 1, 2022 Mar 31, 2022 10-Q 2022-05-09
Q1 2021 -$101M -$48.5M -92.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q1 2020 -$52.2M -$8.44M -19.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-27
Q1 2019 -$43.7M -$21M -92.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-04-28
Q1 2018 -$22.7M Jan 1, 2018 Mar 31, 2018 10-Q 2019-04-29

CRISPR Therapeutics AG Annual Net Cash Provided by (Used in) Operating Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$143M +$118M +45.2% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-11
2023 -$260M +$235M +47.5% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-11
2022 -$496M -$1.03B -192% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-11
2021 $539M +$777M Jan 1, 2021 Dec 31, 2021 10-K 2024-02-21
2020 -$238M -$295M -521% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-21
2019 $56.7M +$153M Jan 1, 2019 Dec 31, 2019 10-K 2022-02-15
2018 -$96.2M -$26.1M -37.3% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-16
2017 -$70.1M -$17.2M -32.6% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-12
2016 -$52.9M Jan 1, 2016 Dec 31, 2016 10-K 2019-02-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.